Toshihiko Kuroda

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector
    Toshihiko Kuroda
    Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 66:10127-35. 2006
  2. ncbi request reprint Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 12:6791-9. 2006
  3. ncbi request reprint Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, CPZN 3800 Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
    Mol Ther 14:789-97. 2006
  4. pmc Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors
    Kaoru Tamura
    Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA
    Mol Ther 21:68-77. 2013
  5. pmc Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases
    Toshihiko Kuroda
    Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    BMC Biotechnol 6:40. 2006
  6. pmc Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors
    Hiroaki Wakimoto
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:3472-81. 2009
  7. pmc Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
    Tooba A Cheema
    Brain Tumor Research Center and Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 110:12006-11. 2013
  8. ncbi request reprint Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system
    Hiroshi Fukuhara
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA
    Cancer Res 65:10663-8. 2005
  9. ncbi request reprint Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction
    Deva S Jeyaretna
    Massachusetts General Hospital, Molecular Neurosurgery Laboratory, Department of Neurosurgery, Boston, MA 02114, USA
    Curr Opin Mol Ther 9:447-66. 2007

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector
    Toshihiko Kuroda
    Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 66:10127-35. 2006
    ..Our results suggest that a transcriptionally regulated oncolytic herpes vector targeting beta-catenin/Tcf signal is very efficacious against CRC tumors carrying an APC gene mutation between the first and second 20-amino-acid repeats...
  2. ncbi request reprint Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 12:6791-9. 2006
    ..Here, we examine the strategy of arming oncolytic HSV with a dominant-negative FGF receptor (dnFGFR) that targets the FGF signaling pathway...
  3. ncbi request reprint Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, CPZN 3800 Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
    Mol Ther 14:789-97. 2006
    ..Enhancing the antiangiogenic properties of oncolytic HSV through the expression of antiangiogenic factors such as PF4 is a powerful new strategy that targets both the tumor cells and tumor vasculature...
  4. pmc Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors
    Kaoru Tamura
    Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA
    Mol Ther 21:68-77. 2013
    ..This study sheds new light on the mechanism by which oHSV and TRAIL function in concert to overcome therapeutic-resistance, and provides an oncolytic virus based platform to target a broad spectrum of different cancer types...
  5. pmc Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases
    Toshihiko Kuroda
    Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    BMC Biotechnol 6:40. 2006
    ..coli. Thus, we sought a method to generate recombinant oncolytic HSV vectors more easily and quickly using BAC technology...
  6. pmc Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors
    Hiroaki Wakimoto
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:3472-81. 2009
    ..This is important for designing new oHSV vectors and clinical trials. Moreover, the new glioma models described in this study provide powerful tools for testing experimental therapeutics and studying invasion and angiogenesis...
  7. pmc Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
    Tooba A Cheema
    Brain Tumor Research Center and Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 110:12006-11. 2013
    ..Taken together, our findings demonstrate that G47Δ-mIL12 provides a multifaceted approach to targeting GSCs, tumor microenvironment, and the immune system, with resultant therapeutic benefit in a stringent glioblastoma model. ..
  8. ncbi request reprint Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system
    Hiroshi Fukuhara
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA
    Cancer Res 65:10663-8. 2005
    ..The results show that "arming" with multiple transgenes can improve the efficacy of oncolytic HSV-1 vectors. The use of our system may facilitate the development and testing of various armed oncolytic HSV-1 vectors...
  9. ncbi request reprint Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction
    Deva S Jeyaretna
    Massachusetts General Hospital, Molecular Neurosurgery Laboratory, Department of Neurosurgery, Boston, MA 02114, USA
    Curr Opin Mol Ther 9:447-66. 2007
    ..This review discusses the current state of research into the development of oncolytic HSV-1 vectors, and highlights the promise that armed oncolytic HSV-1 vectors might hold for the future...